SAN DIEGO, Jan. 10, 2020 /PRNewswire/ -- Shareholder Rights
Law Firm Johnson Fistel, LLP, is investigating potential claims
against Portola Pharmaceuticals, Inc. (NASDAQ:
PTLA) ("Portola " or the "Company") for violations of
federal securities laws.
On January 9, 2020, Portola announced that the drug, Andexxa,
brought in about $28 million in
revenue in the fourth quarter of 2019. Oppenheimer's analyst
covering the stock wrote Andexxa's fourth-quarter revenues "were
well below our $39 million estimate
and $41 million consensus". Following
this news, on January 10, 2020,
Portola stock was down over 43% in
early morning trading.
If you lost money, realized or unrealized on your
Portola
investment, and are interested in learning more about
the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) by email
or phone at 619-814-4471. If emailing, please include a phone
number.
Additionally, you can [click here to join this
action]. There is no cost or obligation to you.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York, and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonfistel.com. Attorney advertising. Past results do
not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
[click here to join this action]
View original
content:http://www.prnewswire.com/news-releases/ptla-alert-johnson-fistel-launches-investigation-into-portola-pharmaceuticals-investors-encouraged-to-contact-firm-300985020.html
SOURCE Johnson Fistel, LLP